BiopharmaceuticalsBiopharmaceuticals

News

Renowned Chemistry of love speaker organizes event in Québec City

News - The Québec City Convention Centre will welcome the International Symposium on Macrocyclic and Supramolecular Chemistry (ISMSC) 2018. More than 600 delegates will gather in Québec City July 8 to 12, 2018. Mr Normand Voyer*, chemist, professor in the Department of Chemistry at Université Laval and Director of PROTEO, convinced board members to hold the Symposium in Québec City. Mr Voyer is a renowned speaker and has given over 100 lectures to more than 20,000 people. The subject? The Chemistry of love.*

GenePOC, Molecular Platform selected by the Canadian food diagnostics industry for the rapid detection of E. coli from beef at food processing facilities.

News - Genome Alberta is pleased to announce on behalf of our funding partners the Alberta Livestock and Meat Agency, Alberta Innovates Bio Solutions, Genome Canada, Genome Quebec, and the Ontario Ministry of Agriculture and Food and the Ministry of Rural Affairs, the results of our collective funding competition for the rapid detection of pathogenic E.coli. Each of the two successful applications will receive $500,000 in new funding. The successful projects will leverage this investment with additional funding to bring the total investment to $1.6 million over the 18 month life of the projects

Medicago announces agreement to be acquired by Mitsubishi Tanabe Pharma in a transaction valued at $357M

News - Medicago announces that it has entered into a definitive arrangement agreement with Mitsubishi Tanabe Pharma Corporation whereby MTPC will acquire all of the issued and outstanding common shares of Medicago, other than the Shares currently held by Philip Morris Investments B.V.

INESSS and Quebec International join forces for the inaugural Health Innovation Week

Press releases - The National Institute for Excellence in Health and Social Services (INESSS) and Quebec International are proud to announce their collaboration on various events during the inaugural Health Innovation Week. The organizations will be holding three events in Quebec City on December 3, 4 and 5, 2013: the Evaluation and Innovative Technology Forum (organized by the INESSS), along with the Quebec City Health Industry Forum and Quebec Seeks Solutions – Health Edition (both organized by Quebec International).

Immune Design and Medicago Announce License Agreement and Collaboration

News - Immune Design, a leader in the field of therapeutic vaccines for cancer, infectious diseases and allergy, and Medicago announced that they have entered a license agreement providing Medicago the use and commercialization of Immune Design's proprietary synthetic Toll-like Receptor 4 agonist, Glucopyranosyl Lipid A (GLA). Medicago has the option to use Immune Design's molecular adjuvant in its vaccines for various pandemic influenza strains.

Plant-based Methods Could Help Fight Flu, Replace Vaccines

News - Medicago Inc, a Quebec City-based biopharmaceutical company, received a patent from the European Patent Office (EPO) that gives the company sole right to produce flu vaccine-like particles in plants this week.

Medicago successfully produces plant-based Rotavirus VLP vaccine candidate

News - edicago announces the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform. Medicago also announced today that an international patent application under the Patent Cooperation Treaty (PCT) that broadly covers plant-produced Rotavirus VLPs has been filed.

Medicago Granted Patent for Influenza Virus-Like Particles in Plants

News - Medicago announces it was granted a patent from the European Patent Office (EPO) providing Medicago the exclusive rights to produce influenza VLPs in plants. Patent Number 2173886, titled "Influenza virus-like particles (VLPs) comprising hemagglutinin produced within a plant", will provide patent coverage for Medicago in Europe through July 2028. The EP 2173886 patent was originally filed on July 11, 2008, and the grant decision is scheduled to be published in the European Patent Bulletin on June 26, 2013.

Medicago Receives Authorization from Health Canada and Commences Phase II Clinical Trial for an H5N1 Vaccine

News - Medicago announces it has received clearance byHealth Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate. All clinical lots have been produced and the trial will commence with interim results expected in the summer of 2013.

Medicago is First in the World to Report Positive Interim Results for its H7N9 Pre-Clinical Trial

News - Medicago reports positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine"). The data show that three micrograms of the H7 vaccine administered with and without adjuvant induced high antibody titers after one dose.

Contacts

Jean-MichelGarroLife Sciences

More details

Newsletter

Subscribe to our newsletter for interesting news and information.

Print this page